CJC-1295 (w/o DAC) + Ipamorelin

This research-grade blend combines CJC-1295 (No DAC), a tetrasubstituted GHRH analog, with Ipamorelin, a selective ghrelin mimetic peptide, for laboratory investigation of growth hormone related biochemical pathways. Peer-reviewed findings describing coordinated GHRH and GHSR pathway activity, including work indexed under PMID: 18420743, highlight the relevance of this combination in multi-receptor mechanistic studies. The blend provides a valuable tool for examining interactions involving GHRH receptor activation, ghrelin receptor (GHSR) signaling, and downstream intracellular mechanisms.

CJC-1295 (No DAC) is widely utilized in vitro to explore short-duration GHRH analog activity, pituitary receptor signaling, and cyclic AMP–mediated intracellular pathways. Ipamorelin is frequently employed to examine selective GHSR-associated cascades, including calcium flux responses, second-messenger formation, and peptide–receptor binding dynamics.

When used in controlled mechanistic models, this blend allows evaluation of complementary pathway modulation, synergistic biochemical effects, and coordinated receptor-specific intracellular signaling. The fixed-ratio formulation ensures consistent composition for in-vitro assays requiring reproducible multi-peptide interaction profiles.